SPONSORED CONTENT BY EXACT SCIENCES

Ultra-personalized CGP for advanced cancers

From the maker of the Oncotype DX® test, the ultra-comprehensive OncoExTra® test offers ultra-personalized genomic profiling through DNA+RNA analysis to uncover more clinically actionable variants and help you find the optimal path forward for your patients with advanced lung cancer and all other advanced solid tumors.1

The OncoExTra test helps you see your patient’s full genomic story by
analyzing:

  • DNA—Thoroughly interrogating ~20,000 genes through whole-exome sequencing
  • RNA—Sequencing all transcripts present through whole-transcriptome sequencing

This comprehensive genomic profiling (CGP) test also offers:

  • Broad and deep sequencing coverage that accurately detects mutations, rare fusions, and transcript variants1
  • High accuracy with 98.8% sensitivity and >99.9% specificity1
  • Optional immunohistochemical (IHC) panels and single stains to provide an added level of detail*
  • Patient-matched tumor-normal sequencing to identify the somatic variants most likely to respond to therapy1

The OncoExTra test delivers all of these insights through an easy-to-interpret report, with the most actionable information highlighted first, to support timely, shared treatment decisions. Report insights include:

  • Targetable variants and fusions (including FDA-approved treatment match)
  • Immuno-oncology signatures (TMB/MSI)
  • Clinical trial eligibility

Don’t miss out on ultra-personalized CGP. Visit booth 1318 at WCLC to see everything the OncoExTra test can do for your patients with advanced lung cancer.

LEARN MORE

*IHC testing not currently available in New York State.

Reference:
1. White et al. Oncotarget. 2021;12(8):726-739.